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Two randomized trials have now established the combination of cisplatin and anantifolate—pemetrexed or raltitrexed—as the standard in the systemic therapy for
mesothelioma.1,2 There remains however a large number of issues to be addressed. Not the
least is whether the choice of the control arm in both trials was appropriate, in the absence
of studies having compared active supportive care (ASC) with and without chemotherapy.
An ongoing study by the British Medical Research Council (MRC)—randomizing
between ASC, ASC with single agent vinorelbine and ASC with mitomycin, vindesine
and cisplatin (MVP)—will hopefully address the issue in analogy to what has been
observed in non-small cell lung cancer (NSCLC). In the mean time, indirect evidence
comes from both abovementioned trials, as it is unlikely that single agent cisplatin will
reduce survival in this patient population. Furthermore, a recent small randomized study
comes closest to answering the question.3 Good performance patients with stable symp-
toms were randomized between immediate chemotherapy, consisting of MVP, or the same
chemotherapy at symptomatic progression. In the latter arm, chemotherapy was delayed
with a median of 4 months, and five patients never received any. In those who actually
received chemotherapy, immediate treatment was associated with a significantly longer
time to symptomatic progression and a trend to improved overall survival: 66% at 1 year
compared to the “delayed” patients (36%), whose quality of life was less well maintained.
Whether the true improvement in median survival with chemotherapy will be in the
observed magnitude of 3–4 months is doubtful. As is the case in advanced NSCLC, the
estimated median improvement in a general mesothelioma population eligible for plati-
num-based chemotherapy will probably average 8–10 weeks.
The next issue then becomes what to consider as the standard regimen. Although
strictly speaking, head-to-head comparisons between cisplatin/pemetrexed, cisplatin/
raltitrexed, MVP, or vinorelbine need to be conducted, it is foreseeable that, also in
analogy with NSCLC, none of these regimens will prove to be superior and that criteria
other than outcome will become decisive: toxicity, compliance, ease of administration.
Determining whether this amounts to a noninferiority of these regimens will require trials
with sample sizes that are out of reach for a disease that is rare.
Similarly, in view of their observed single agent activity in mesothelioma, one might
question whether single-agent pemetrexed or raltitrexed would not have been the better
comparator in the randomization.4,5 The use of single agent cisplatin, although moderately
active, is distinctly unusual in current practice. Most clinicians would have associated
either a third generation drug or an anthracycline.
What is the impact of the administration of vitamins on mesothelioma chemother-
apy? Although there is no scientific rationale that vitamins per se are active against
mesothelioma, one could argue that systemic toxicity might be affected by vitamins. B12
and folic acid could “rescue” the bone marrow. In the pemetrexed study, patients on the
cisplatin only arm appeared to have improved their toxicity profile when given vitamins.1
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Furthermore, the statistical significance in outcome was lost
in the subgroup of patients supplemented with vitamins. This
might reflect a loss of power by the smaller sample size, a
neutralization of the activity of pemetrexed, or a potentiation
of the activity of cisplatin. The latter explanation is doubtful
because responses and outcome in the cisplatin arms are
similar in both folate trials.
What is the optimal dose of the antifolates? The phase
I studies defined a maximum tolerated dose (MTD) based on
pemetrexed being given without vitamin support. With vita-
min support, it appears that the MTD would be much higher.
The results of a randomized trial exploring two dose levels of
pemetrexed with cisplatin and vitamins are expected. It is
tempting to speculate that a subgroup of patients with high
concentrations of intracellular target enzymes could benefit
more from higher doses of antifolates when adequately substi-
tuted with vitamins. Pharmacogenomically tailored antifolate
administration might then well open new treatment perspectives.
A next set of issues is reminiscent of hypotheses al-
ready investigated at length in NSCLC: duration of treatment,
value of maintenance single agent antifolate, cis- or carbo-
platin based regimens, drug substitution, platinum versus
nonplatinum based regimens, adding a third agent to an active
doublet. The pemetrexed study reached a median number of
cycles of six, compared with four with cisplatin/raltitrexed.
Trials looking at the optimal number of cycles should start
from these figures and compare them with either more or
fewer cycles. A preliminary uncontrolled report of mainte-
nance pemetrexed in 13 patients obtaining response after
induction combination treatment shows a better outcome as
compared to 14 patients not treated with maintenance.6 There
are promising phase II results with combinations of pem-
etrexed combined with oxaliplatin, carboplatin or gemcitab-
ine. 7–9 The latter two combinations will move into a com-
parative trial. It is however, regrettably foreseeable that the
outcome of these issues will not be different from those
observed in NSCLC: all platinum based combinations are
equivalent, platinum and nonplatinum are equivalent, all
doublets are equivalent and triplets add nothing but toxicity.
One might even question whether trials investigating such
comparisons need even to be performed in the light of the
small number of patients available for clinical trials.
Novel antifolates are being designed using a high res-
olution crystal structure of the intracellular enzymes involved
in folate metabolism. Improvements in chemotherapy for
mesothelioma might primarily come from the use of molec-
ularly targeted drugs such as nolatrexed, binding to the folate
cofactor binding site of thymidilate synthase.10 Unfortunately
its development was halted after negative studies.11
With the high response rate observed with cisplatin-
antifolate combinations, investigators recently turned to these
regimens as neoadjuvant ones. Two multicentric series in
early stage patients have been reported so far, observing a
response rate of 32–40%.12,13 The regimens appeared safe,
with a high number of patients having resections. Contrary to
observations in other neoadjuvant series, no pathologic com-
plete remission or evidence of tumor necrosis, was reported
in the resection specimens. The report in this issue by Flores
et al. illustrates the challenges faced by investigators with this
multimodality approach in more advanced stages.14 Only
seven of the 37 patients who initially were supposed to be
accrued underwent the full therapy that the trial was designed
to evaluate. The true value of induction chemotherapy in a
multimodality setting will, however, have to wait for the
results of phase III trials, one of which has recently started15
Despite doubts about the design of both published
randomized trials, cisplatin and an antifolate should be con-
sidered the standard-of-care, first-line treatment of selected
patients with malignant mesothelioma against which future
treatments will have to be compared. The odds are against
major further improvements by substitution of drugs or new
combinations of existing drugs. Further progress should come
from the (addition of) novel drugs or targeted agents, first to
be tested in refractory patients.
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